›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:SafeSEQ AML MRD Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sysmex CorpType:
Laboratory Developed Test
Related tests:
SafeSEQ technology delivers best-in-class, ultra-sensitive NGS liquid biopsy solutions to identify tumor mutations across cancer types for a range of intended uses, including to better-inform therapy selection, dynamically monitor tumor response, identify molecular mediators of resistance, and detect minimal residual disease at a variant level that is an order of magnitude more sensitive than other methods.
Cancer:
Acute Myelogenous Leukemia
Gene:
BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), FLT3 (Fms-related tyrosine kinase 3), GATA2 (GATA Binding Protein 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
See More ...
BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), FLT3 (Fms-related tyrosine kinase 3), GATA2 (GATA Binding Protein 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), NPM1 (Nucleophosmin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), SETBP1 (SET Binding Protein 1), SF3B1 (Splicing Factor 3b Subunit 1), SRSF2 (Serine and arginine rich splicing factor 2), TP53 (Tumor protein P53), U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
Method:
Next-Generation Sequencing (NGS)